GoodRx Holdings, Inc. (NASDAQ:GDRX) Receives Average Rating of “Hold” from Brokerages

GoodRx Holdings, Inc. (NASDAQ:GDRX) has been assigned an average rating of “Hold” from the fifteen brokerages that are covering the firm, MarketBeat Ratings reports. Three analysts have rated the stock with a sell rating, seven have given a hold rating and five have given a buy rating to the company. The average 1 year target price among brokers that have covered the stock in the last year is $3.8125.

Several equities analysts have commented on GDRX shares. Wells Fargo & Company lowered their price target on GoodRx from $7.00 to $3.50 and set an “overweight” rating on the stock in a report on Wednesday, March 4th. Leerink Partners reiterated an “outperform” rating and set a $3.00 price target on shares of GoodRx in a report on Thursday, February 26th. Weiss Ratings downgraded GoodRx from a “sell (d+)” rating to a “sell (d)” rating in a report on Wednesday, May 20th. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of GoodRx in a report on Friday, February 27th. Finally, The Goldman Sachs Group reiterated a “neutral” rating and set a $3.50 price target on shares of GoodRx in a report on Friday, May 8th.

GoodRx Trading Up 3.4%

NASDAQ:GDRX opened at $2.76 on Thursday. The stock’s 50 day moving average price is $2.60 and its 200 day moving average price is $2.48. GoodRx has a 52 week low of $1.77 and a 52 week high of $5.81. The company has a market capitalization of $945.49 million, a P/E ratio of 46.01, a P/E/G ratio of 1.24 and a beta of 1.61. The company has a debt-to-equity ratio of 0.78, a quick ratio of 1.47 and a current ratio of 1.47.

GoodRx (NASDAQ:GDRX) last released its quarterly earnings data on Wednesday, May 6th. The company reported $0.07 EPS for the quarter, hitting analysts’ consensus estimates of $0.07. GoodRx had a return on equity of 7.90% and a net margin of 2.61%.The firm had revenue of $194.01 million for the quarter, compared to the consensus estimate of $185.40 million. During the same quarter in the prior year, the company posted $0.09 earnings per share. The firm’s revenue was down 4.4% on a year-over-year basis. On average, research analysts forecast that GoodRx will post 0.17 EPS for the current fiscal year.

Hedge Funds Weigh In On GoodRx

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Essential Partners LLC grew its holdings in GoodRx by 375.4% during the first quarter. Essential Partners LLC now owns 14,304 shares of the company’s stock valued at $28,000 after purchasing an additional 11,295 shares during the last quarter. Meridian Wealth Management LLC acquired a new stake in shares of GoodRx in the fourth quarter worth $29,000. SG Americas Securities LLC acquired a new stake in shares of GoodRx in the first quarter worth $29,000. Krilogy Financial LLC acquired a new stake in shares of GoodRx in the first quarter worth $33,000. Finally, Quarry LP acquired a new stake in shares of GoodRx in the third quarter worth $33,000. Institutional investors and hedge funds own 63.77% of the company’s stock.

GoodRx Company Profile

GoodRx Holdings, Inc (NASDAQ: GDRX) operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.

In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.